Strong Industry Recognition BrightInsight has been recognized as the 2023 Frost & Sullivan Global Company of the Year and ranked 307th on the Deloitte Technology Fast 500, highlighting its rapid growth and industry leadership in digital health solutions which can attract prospective clients seeking proven expertise and credibility.

Expanding Digital Health Offerings Recent launches of patient companion apps for groundbreaking gene therapies and the integration of AI-powered chatbots demonstrate BrightInsight’s commitment to innovative, patient-centric digital solutions, creating opportunities to upsell enhanced digital services to biopharma and medtech firms.

Global Market Expansion The company's successful rollout of apps across North America, Japan, Canada, and Latin America indicates a growth-oriented approach and readiness to support clients’ international digital health strategies, making it a valuable partner for companies seeking global compliance and deployment.

Strategic Partnerships Partnerships like the recent collaboration with FPT Group for co-developing digital healthcare platforms expose opportunities to integrate BrightInsight’s cloud-based solutions into broader health ecosystems, appealing to life sciences firms looking to expand their digital infrastructure.

Robust Financial Backing With a funding of $166 million and revenue between $10M and $50M, BrightInsight is well-capitalized to invest in new digital health innovations, making it an appealing partner for organizations seeking scalable and future-ready digital transformation solutions.